Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cns Pharmaceuticals Inc
(NQ:
CNSP
)
0.1555
-0.0117 (-7.00%)
Streaming Delayed Price
Updated: 1:26 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cns Pharmaceuticals Inc
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment
September 19, 2022
Via
Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM
September 16, 2022
Via
Investor Brand Network
Focused Ultrasound May Offer Easier Way to Treat Brain Tumors Effectively
September 15, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials
September 13, 2022
Via
Investor Brand Network
Study Suggests That Test of Memory May Signal Brain Tumor Presence
July 07, 2022
Via
Investor Brand Network
12 Health Care Stocks Moving In Monday's After-Market Session
September 12, 2022
Gainers OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of 927.4K shares come close, making up 324.6% of its average volume over...
Via
Benzinga
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field
September 09, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin
September 07, 2022
Via
Investor Brand Network
Accessibility Issues Prevent Individuals in Rural Areas from Undergoing Lifesaving Tumor Treatment
September 07, 2022
Via
Investor Brand Network
Topics
Death
Exposures
Death
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research
September 01, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product
August 30, 2022
Via
Investor Brand Network
Study Looks into Why Deadly Brain Tumors Continue to Grow After Treatment
August 29, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin
August 23, 2022
Via
Investor Brand Network
Targeted Cancer Vaccines Show Promise in Halting Tumor Progression
August 19, 2022
Via
Investor Brand Network
Topics
Death
Exposures
Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update
August 15, 2022
Via
Investor Brand Network
Exposures
Product Safety
Researchers Want to Manage Cancer By Keeping Malignant Cells Restricted in Place
August 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success
August 12, 2022
Via
Investor Brand Network
Exposures
Product Safety
Study Finds That Ketogenic Diet May Help Patients with Brain Cancer
August 04, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market
August 04, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment
August 02, 2022
Via
Investor Brand Network
Researchers Develop Blood Test to Improve Tumor Diagnosis, Monitoring
July 27, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Urges Shareholders to Vote in Favor of Proxy Proposals for Upcoming Annual Meeting
July 25, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial
July 20, 2022
Via
Investor Brand Network
Preclinical Study Uncovers Potential Key to Treating Deadly Brain Tumors
July 18, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expands Patient Eligibility for Brain Cancer Drug Trial, Receives Approval from U.S. FDA for Protocol Amendment
July 11, 2022
Via
Investor Brand Network
Exposures
Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
July 07, 2022
Via
Benzinga
AI May Help Improve Brain Cancer Diagnosis
June 29, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval for Protocol Amendment to Ongoing Potentially Pivotal Berubicin Trial
June 23, 2022
Via
Investor Brand Network
Exposures
Product Safety
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
June 23, 2022
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.